Skip to main content
. 2023 Jun 21;10(24):2300881. doi: 10.1002/advs.202300881

Figure 6.

Figure 6

ANO1 promotes cancer progression and impairs immunotherapeutic efficacy through inhibiting ferroptosis. A) RNA‐sequencing identified genes upregulated in HGC27 cell after ANO1 knockdown were proceeded for KEGG enrichment analysis. B) Pearson correlation between expressions of ANO1 and NFE2L2/SLC7A11 in TCGA‐STAD dataset. Expression of ferroptotic proteins after C) ANO1 knockdown or D) overexpression (oe) were assessed. The levels of E) lipid ROS and F) MDA after ANO1 knockdown or overexpression were assessed. G) Lipid ROS and H) MDA repressed by ANO1 overexpression was rescued by ferroptosis agonist erastin. I) Expression of ferroptotic proteins in MC38‐R CDX after acquired resistance to anti‐PD‐1 antibody. The in vitro J) proliferation and K) invasiveness suppressed by ANO1 knockdown were reversed by ferroptosis inhibitor Fer‐1. L) The sensitized anti‐tumor effectiveness in CT26 CDX by combining ANO1 knockdown and anti‐PD1 antibodies was alleviated by ferroptosis inhibitor liproxstatin (Lipro). The color scale from blue to red reflected the p value from 1 to 0 (the smaller, the more significant). *p < 0.05. Error bars, mean ± SEM.